These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2104546)

  • 1. From the National Institutes of Health.
    Raub W
    JAMA; 1990 Jan; 263(1):21. PubMed ID: 2104546
    [No Abstract]   [Full Text] [Related]  

  • 2. [Danazol and autoimmune thrombocytopenia in systemic lupus erythematosus].
    Selva A; Jordana R; Tolosa C; Ordi J
    Med Clin (Barc); 1990 Apr; 94(14):557-8. PubMed ID: 2355774
    [No Abstract]   [Full Text] [Related]  

  • 3. Danazol therapy in patients with immune cytopenias.
    Manoharan A
    Aust N Z J Med; 1987 Dec; 17(6):613-4. PubMed ID: 3447572
    [No Abstract]   [Full Text] [Related]  

  • 4. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus.
    West SG; Johnson SC
    Ann Intern Med; 1988 May; 108(5):703-6. PubMed ID: 3358571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with danazol for refractory thrombocytopenia in rheumatoid arthritis.
    Dasgupta B; Grahame R
    Br J Rheumatol; 1989 Dec; 28(6):550-2. PubMed ID: 2590815
    [No Abstract]   [Full Text] [Related]  

  • 6. Sonographic diagnosis of venocclusive disease of the liver and danazol therapy for autoimmune thrombocytopenia in an autologous marrow transplant patient.
    Matsuishi E; Anzai K; Dohmen K; Taniguchi S; Gondo H; Kudo J; Shibuya T; Ishibashi H; Harada M; Niho Y
    Jpn J Clin Oncol; 1990 Jun; 20(2):188-92. PubMed ID: 2196389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Danazol for lupus thrombocytopenia.
    Marino C; Cook P
    Arch Intern Med; 1985 Dec; 145(12):2251-2. PubMed ID: 4074040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Danazol in refractory autoimmune thrombocytopenic purpura (ATP). A new therapeutic sequence.
    Ambriz-Fernández R; Chávez-Sánchez G; Pizzuto-Chávez J; Morales-Polanco MR; Aviles-Miranda A
    Arch Invest Med (Mex); 1985; 16(3):295-304. PubMed ID: 3833096
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy of danazol in the treatment of thrombopenia in a chronic HIV-seropositive hemodialyzed patient. Unexpected appearance of major hyperglycemia].
    Morinière P; Gross S; Lalau JD; Schmit JL; Westeel PF; Ruiz JC; Claisse JF; Andrejak M; Fournier A
    Ann Med Interne (Paris); 1989; 140(8):735-7. PubMed ID: 2629573
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
    Trebini F; Daniele D; Gillio S; Scarzella L
    Acta Neurol (Napoli); 1985 Oct; 7(5):432-9. PubMed ID: 3933283
    [No Abstract]   [Full Text] [Related]  

  • 11. [The use of L-deprenyl in Parkinson's disease].
    Zhonghua Yi Xue Za Zhi; 1983 Mar; 63(3):147-9. PubMed ID: 6409375
    [No Abstract]   [Full Text] [Related]  

  • 12. Why another anti-Parkinson drug?
    Shreeve C
    Nurs Mirror; 1984 Feb; 158(9):38-40. PubMed ID: 6422448
    [No Abstract]   [Full Text] [Related]  

  • 13. Danazol for Evan's syndrome due to SLE.
    Aranegui P; Giner P; Lopez-Gomez M; el Amrani A; Jimenez-Alonso J
    DICP; 1990 Jun; 24(6):641-2. PubMed ID: 2360344
    [No Abstract]   [Full Text] [Related]  

  • 14. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 15. [A new drug for Parkinson's disease: selegiline (Eldeprine). Copenhagen, January 26-27, 1989].
    D'Anglejan-Chatillon J
    Rev Prat; 1989 Oct; 39(22):1978. PubMed ID: 2510243
    [No Abstract]   [Full Text] [Related]  

  • 16. Selegiline and Parkinson's disease. Protective and symptomatic considerations.
    Golbe LI; Langston JW; Shoulson I
    Drugs; 1990 May; 39(5):646-51. PubMed ID: 2112994
    [No Abstract]   [Full Text] [Related]  

  • 17. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of danazol in the management of chronic immune thrombocytopenic purpura.
    McVerry BA; Auger M; Bellingham AJ
    Br J Haematol; 1985 Sep; 61(1):145-8. PubMed ID: 4052322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987.
    J Neural Transm Suppl; 1987; 25():1-197. PubMed ID: 3123595
    [No Abstract]   [Full Text] [Related]  

  • 20. Parkinson's disease: can we influence progression?
    Quinn N
    Br J Hosp Med; 1990 May; 43(5):327. PubMed ID: 2114189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.